Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 33c; Offers Guidance

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($0.07), $0.33 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $103.54 million versus the consensus estimate of $86.38 million.

GUIDANCE:

Castle Biosciences Inc. sees FY2026 revenue of $365-375 million, versus the consensus of $352.3 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• S&P shares jump report of potential CapIQ spinout
• Active options: AAPL NVDA TSLA MU AMZN META SPCX INTC MSFT ORCL
• S&P Weighs Multibillion-Dollar Spinout of Data Platform CapIQ - Bloomberg